Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Malaria

Malaria

Subtypes of Malaria

Plasmodium falciparum Malaria 2

22 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Malaria

123 trials tracked for Malaria: 27 in phase 3 or 4 and 18 with published results. The most-cited published study has 239 citations.

123Trials tracked
27Phase 3 & 4
0Recruiting
18With published results
Phase distribution
Phase 4 5 Phase 3 22 Phase 2 36 Phase 1 41 Other / NA 19
  1. Phase 3 Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants Completed · 239 cited
  2. Phase 3 Novel Use Of Hydroxyurea in an African Region With Malaria Completed · 150 cited
  3. Phase 3 Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients Completed · 143 cited
  4. Phase 3 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed · 143 cited
  5. Phase 3 Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Completed · 129 cited
  6. Phase 3 HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children Completed · 111 cited
Show 44 more trials
  1. Phase 3 Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria Completed · 108 cited
  2. Phase 3 Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients Completed · 90 cited
  3. Phase 3 An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa Completed · 70 cited
  4. Phase 3 Intermittent Preventive Treatment of Malaria in Schoolchildren Completed · 64 cited
  5. Phase 3 Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women Completed · 51 cited
  6. Phase 4 A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh Completed · 48 cited
  7. Phase 3 Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2) Completed · 46 cited
  8. Phase 3 Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children Completed · 34 cited
  9. Phase 3 Repeat Ivermectin Mass Drug Administrations for MALaria Control II Completed · 24 cited
  10. Phase 3 Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa Completed · 12 cited
  11. Phase 3 Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda Completed · 11 cited
  12. Phase 4 Gut and Azithromycin Mechanisms in Infants and Children II Completed · 5 cited
  13. Phase 4 Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa Completed
  14. Phase 4 Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function Completed
  15. Phase 4 A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®) Completed
  16. Phase 3 Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children Completed
  17. Phase 3 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. Completed
  18. Phase 3 Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon Completed
  19. Phase 3 Chemopreventive Therapy for Malaria in Ugandan Children Completed
  20. Phase 3 Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) Completed
  21. Phase 3 Chloroquine for Malaria in Pregnancy Completed
  22. Phase 2 Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region Completed
  23. Phase 2 Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen Completed
  24. Phase 2 OZ439 PhIIa Study in Plasmodium Falciparum: Extended Observation Completed
  25. Phase 2 Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Completed
  26. Phase 2 Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine Completed
  27. Phase 2 Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children. Completed
  28. Phase 2 Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria Completed
  29. Phase 2 Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers Completed
  30. Phase 2 A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant Completed
  31. Phase 2 A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults Completed
  32. Phase 2 PfSPZ Vaccine Trial in Malian Children Completed
  33. Phase 2 Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa... Completed
  34. Phase 2 Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali Completed
  35. Phase 2 Safety and Efficacy Study of IV Artesunate to Treat Malaria Completed
  36. Phase 2 Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed
  37. Phase 2 Weekly Dosing of Malarone ® for Prevention of Malaria Completed
  38. Phase 2 A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection Completed
  39. Phase 2 Studies of a Candidate Aminoquinoline Antimalarial (AQ-13) Completed
  40. Phase 2 Aggressive Antipyretics for Fever Reduction in CNS Malaria Completed
  41. Phase 2 L9LS MAb in Malian Adults Completed
  42. Phase 2 A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate Completed
  43. Phase 2 Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults Completed
  44. Phase 2 Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria. Completed

Showing the 50 most-cited and recently-updated of 123 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Malaria: what the trials found

Several antimalarial regimens have demonstrated high efficacy in clinical and parasitological outcomes. Pyronaridine artesunate showed high crude cure rates at days 21 and 28 13 and a PCR-corrected adequate clinical and parasitological response (ACPR) rate of approximately 97.6% to 98.8% on day 28 14, with nearly 100% success on day 14 14. Additionally, pyronaridine artesunate showed a high PCR-corrected ACPR rate of over 99% on day 28 in another study 9.

Treatment regimens including Artesunate-mefloquine demonstrated high PCR-adjusted malaria cure rates (over 98%) at days 14, 28, and 42 6. Chloroquine was associated with zero instances of severe anemia (Hb <7g/dl) or recurrence of parasitemia within 16 days of follow-up 2.

Vaccine studies for Malaria Vaccine 257049 showed a significant reduction in the rate of first or only clinical episodes of Plasmodium falciparum malaria infection (CPFMI) compared to control groups 21. However, this vaccine was associated with a statistically significant increase in the incidence of clinical malaria meeting specific case definitions 15.

Prophylactic and preventive measures include monthly dihydroartemisinin-piperaquine for pregnant women 7, which showed no significant difference in maternal parasitemia at delivery or placental malaria compared to controls 18. Monthly sulfadoxine-pyrimethamine (SP) during pregnancy was associated with a mean gestational age of approximately 39.5 weeks 11. Lopinavir/Ritonavir showed no significant difference in the prevalence of placental malaria across different measures 17, though it showed a statistically significant difference in the incidence-density of malaria episodes per time at risk 12.

Recent results — preliminary, needs further review

  • [ ] The PfSPZ Vaccine is currently undergoing Phase 2 evaluation 1.

For the clinician treating this condition

  • Pyronaridine artesunate demonstrates high efficacy and rapid clearance of parasites, with nearly 100% PCR-corrected ACPR at day 14 14.
  • Artesunate-mefloquine shows high cure rates (over 98%) through day 42 6.
  • Malaria Vaccine 257049 significantly reduces the rate of first or only clinical episodes of P. falciparum infection, though it is associated with higher incidences of certain clinical malaria case definitions [15, 21].

AI synthesis of 13 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SP+AQ cuts malaria incidence 54.6% versus SP alone in African children
Infectious Disease Sys. Review
SP+AQ cuts malaria incidence 54.6% versus SP alone in African children Adding amodiaquine to sulfadoxine-pyrimethamine reduces malaria in children
This meta-analysis of 32 sites across 13 African countries found that sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ) reduced malaria inc…
Combining two medicines significantly lowers malaria rates in children across Africa compared to using only one drug.
medRxiv Jul 19, 2026
Schistosomiasis infection increases odds of malaria co-infection by 1.27 in children and adolescents
Pediatrics Meta-analysis
Schistosomiasis infection increases odds of malaria co-infection by 1.27 in children and adolescents Schistosomiasis infection increases risk of malaria in African children
This systematic review and meta-analysis of 30 studies involving children and adolescents in Sub-Saharan Africa indicates that schistosomias…
Children with schistosomiasis have higher odds of also having malaria, especially those who have direct contact with water.
Jun 16, 2026
Pfkelch13 mutations occur in 6% of Plasmodium falciparum isolates across various African regions
Genetics & Precision Medicine Meta-analysis
Pfkelch13 mutations occur in 6% of Plasmodium falciparum isolates across various African regions New Data Shows Regional Differences in Malaria Drug Resistance
This meta-analysis of observational cohort studies evaluates the prevalence of pfkelch13 mutations in Plasmodium falciparum isolates from pa…
New research reveals varying levels of a specific genetic mutation that may link to reduced effectiveness of malaria treatments across Afric…
medRxiv Jun 11, 2026
Malaria vaccines RTS,S/AS01 and R21/Matrix-M reduce malaria risk in children
Pediatrics Meta-analysis
Malaria vaccines RTS,S/AS01 and R21/Matrix-M reduce malaria risk in children Malaria vaccines cut risk by 23% in infants, 39% in toddlers
This systematic review and meta-analysis of 8 studies found that RTS,S/AS01 and R21/Matrix-M vaccines reduce malaria risk in children. In th…
Two malaria vaccines, RTS,S and R21, reduce malaria risk by 23% in young infants and 39% in older children, a review finds.
Jun 7, 2026
One in six blood donors in Cameroon carries Plasmodium infection, meta-analysis finds
Infectious Disease Meta-analysis
One in six blood donors in Cameroon carries Plasmodium infection, meta-analysis finds 1 in 6 blood donors in Cameroon carries malaria parasite
A systematic review and meta-analysis of 18 studies (~12,500 donations) found a 16.6% pooled prevalence of Plasmodium spp. in Cameroonian bl…
A review of 18 studies finds 16.6% of blood donations in Cameroon contain Plasmodium, the malaria parasite.
May 30, 2026
Clinical and laboratory abnormalities linked to higher mortality in malaria patients with acute kidney injury
Hematology Meta-analysis
Clinical and laboratory abnormalities linked to higher mortality in malaria patients with acute kidney injury Severe lab changes in malaria patients with kidney injury strongly predict death
This systematic review and meta-analysis evaluated the relationship between various clinical and laboratory abnormalities and mortality in m…
Severe lab changes like low blood pressure or breathing trouble in malaria patients with kidney injury greatly increase the risk of dying.
May 26, 2026
Review of Malaria literature lacks reported data on interventions and outcomes
Infectious Disease Sys. Review
Review of Malaria literature lacks reported data on interventions and outcomes Review of malaria treatments shows what doctors need to know
This narrative review addresses malaria but does not report specific interventions, populations, or outcomes. The authors note that key deta…
This review of malaria treatments offers important information for doctors and patients facing this serious infection.
Frontiers May 17, 2026
Narrative review links chronic hemozoin exposure to prostate cancer development in malaria regions
Oncology Sys. Review
Narrative review links chronic hemozoin exposure to prostate cancer development in malaria regions Malaria Byproduct May Fuel Prostate Cancer Growth
This narrative review explores the hypothesis that chronic exposure to hemozoin from malaria may contribute to prostate cancer development. …
A byproduct left behind by malaria parasites may fuel prostate cancer by keeping the immune system in a constant state of low-grade inflamma…
Frontiers May 4, 2026
Iron micronutrient powders reduce malaria-induced anaemia but not growth in young children
Nutrition & Obesity Medicine RCT
Iron micronutrient powders reduce malaria-induced anaemia but not growth in young children Iron powders reduce malaria-related anaemia in young children
This cluster-randomized trial in 1,806 Ghanaian children aged 6-35 months found that daily iron-containing micronutrient powders for five mo…
Daily iron-based micronutrient powders can lower the risk of malaria-induced anaemia in preschool children in Ghana.
medRxiv Apr 27, 2026
L9LS monoclonal antibody reduces malaria infection in children in western Kenya
Pediatrics RCT
L9LS monoclonal antibody reduces malaria infection in children in western Kenya A malaria shot for babies shows real protection in Kenya
This randomized controlled trial evaluated the L9LS monoclonal antibody in infants and children in a high perennial malaria transmission set…
A long-acting antibody shot reduced malaria infections by 43% in young children in Kenya, with no major safety concerns.
Apr 27, 2026
Narrative review outlines VLP engineering strategies for broadly protective vaccines against multiple viral pathogens
Infectious Disease Sys. Review
Narrative review outlines VLP engineering strategies for broadly protective vaccines against multiple viral pathogens New Vaccine Map Helps Pick Best Tools
This narrative review examines virus-like particle (VLP) engineering strategies, including genetic fusion, modular conjugation, and nucleic …
Imagine trying to fix a leaky roof with every tool in the shed.
Frontiers Apr 23, 2026
Observational cross-sectional study on environmental covariates and malaria prevalence in Tanzania
Infectious Disease
Observational cross-sectional study on environmental covariates and malaria prevalence in Tanzania Does the grass and shrubs near your home affect malaria risk?
This observational cross-sectional study in Mainland Tanzania examined household-level environmental covariates and malaria parasite prevale…
This matters because where you live can change your family's malaria risk.
medRxiv Apr 19, 2026

Questions about Malaria

Can virus-like particles be engineered to protect against malaria?

Yes, virus-like particles (VLPs) can be engineered to protect against malaria, with studies showing they can display malaria antigens and induce protective immune responses in animals.

Full answer →

All Malaria Articles